Immune Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Immune Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: TGD001 Treatment in Thrombotic Microangiopathies [Phase 1, Phase 2]
Clinical trial update for TGD001 in thrombotic microangiopathy and immune thrombocytopenia, currently not recruiting for Phase 1/Phase 2.
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients [Phase 3]
This update announces a Phase 3 safety and efficacy trial of QL0911 for pediatric immune thrombocytopenia that is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) [Phase 1]
This clinical trial update describes a Phase 1 study of PN20 in adults with primary immune thrombocytopenia (ITP). The sponsor is Chongqing …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases [EARLY_Phase 1]
This entry describes an early-phase UCAR-T trial targeting CD19/BCMA for autoimmune hematologic diseases and notes that recruitment is ongoi…
-
EMA approval · 2026-02-25EMA Authorised: Eltrombopag Accord (eltrombopag olamine) — Accord Healthcare S.L.U.
The EU's EMA authorised the brand product Eltrombopag Accord (eltrombopag olamine) for treatment of immune thrombocytopenia. The marketing a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) [Phase 3]
Phase 3 study evaluating rilzabrutinib in adults and adolescents with persistent or chronic immune thrombocytopenia has results posted and t…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia [EARLY_Phase 1]
An early-phase clinical trial is evaluating the safety and preliminary efficacy of QT-019C, a universal allogeneic CAR-T therapy targeting C…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection [Phase 2]
A Phase 2 study evaluating eltrombopag for immune thrombocytopenia in patients with chronic hepatitis B infection has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia [NA]
This clinical trial update reports on low-dose rituximab regimens in Chinese adults with immune thrombocytopenia and notes the study status …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
This clinical trial update shows a recruiting longitudinal pediatric cohort study of primary immune thrombocytopenia in children. The study …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) [Phase 2]
Phase 2 clinical trial in China evaluating rituximab with an anti-CD38 monoclonal antibody versus rituximab alone for primary immune thrombo…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) [Phase 2]
This Phase 2 clinical trial is evaluating an anti-CD38 monoclonal antibody versus Rituximab for the management of primary immune thrombocyto…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy [Phase 2]
Phase II clinical trial evaluating orelabrutinib in combination with romiplostim for primary immune thrombocytopenia; study status is not ye…
-
EMA approval · 2026-02-05EMA Authorised: Eltrombopag Viatris (eltrombopag olamine) — Viatris Limited
The EMA authorised Viatris' eltrombopag olamine (Eltrombopag Viatris) for immune thrombocytopenia (idiopathic thrombocytopenic purpura), est…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis [NA]
This clinical trial is investigating anti-platelet antibodies detected with the MAIPA assay to demonstrate the autoimmune nature of thromboc…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of bortezomib for relapsed/refractory immune thrombocytopenia and is currentl…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
A completed clinical trial examining the molecular relationship between platelets and tumor cells in patients with immune thrombocytopenia a…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP [Phase 2]
A Phase 2 multicenter randomized open-label trial compares diammonium glycyrrhizinate enteric-coated capsules plus dexamethasone versus dexa…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
Sanofi-sponsored clinical trial evaluating cognitive status, fatigue, and inflammation in adults with immune thrombocytopenia has completed.…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) [Phase 2]
This Clinical Trial Update reports a Phase 2 study comparing daratumumab to rituximab for pediatric primary immune thrombocytopenia, with re…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) [Phase 2]
A Phase 2 trial in China is evaluating an anti-CD38 monoclonal antibody in combination with rituximab for primary immune thrombocytopenia an…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) [Phase 2]
Phase 2 trial (TAI-SHAN11) of DZD8586 in adults with primary immune thrombocytopenia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: V-IMMUNE® for Immune Thrombocytopenia [Phase 3]
A Phase 3 clinical trial of V-IMMUNE for immune thrombocytopenia is actively recruiting.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) [Phase 1, Phase 2]
This document provides an update on an ongoing Phase Ib/II clinical trial of STSA-1301, a subcutaneous therapy, for primary immune thrombocy…
-
FDA approval · 2026-01-15FDA Approved: ALVAIZ — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's supplemental application for ALVAIZ (eltrombopag).